Shots:
- Upstream Bio presented results from the P-II VALIANT study evaluating verekitug in 478 adults with severe asthma, with the study meeting its 1EP of reducing the annualized asthma exacerbation rate (AAER) across all dose regimens.
- Verekitug 100 mg dosed every 12 wks. reduced AAER by 56% vs. PBO (p<0.001) and also improved lung function (FEV1), exhaled nitric oxide (FeNO), and asthma symptom control measured by ACQ-6 at wk. 24, with improvements observed as early as wk. 2 across all 2EP
- Verekitug was well tolerated across active doses, and Upstream Bio will initiate a P-III study in severe asthma and CRSwNP in Q1’27, evaluating a 400 mg quarterly regimen in broad patient populations
Ref: GlobeNewswire | Image: Upstream Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
